Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,180
-10 (-0.07%)
May 2, 2025, 3:30 PM KST
-31.31%
Market Cap 364.17B
Revenue (ttm) 2.36B
Net Income (ttm) -10.24B
Shares Out 23.99M
EPS (ttm) -429.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 99,056
Average Volume 68,853
Open 15,220
Previous Close 15,190
Day's Range 14,970 - 15,750
52-Week Range 12,010 - 26,000
Beta 0.09
RSI 47.51
Earnings Date May 13, 2025

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2024, Genomictree's revenue was 2.36 billion, a decrease of -30.89% compared to the previous year's 3.42 billion. Losses were -10.24 billion, 17.0% more than in 2023.

Financial Statements

News

There is no news available yet.